Loading clinical trials...
Loading clinical trials...
A Randomized Phase 3 Study of MRTX849 Versus Docetaxel in Patients With Previously Treated Non-Small Cell Lung Cancer With KRAS G12C Mutation
Conditions
Interventions
MRTX849
Docetaxel
Locations
343
United States
Local Institution - 012-898
Cerritos, California, United States
City of Hope - Duarte (Main Campus)
Duarte, California, United States
Local Institution - 012-898 D
Glendale, California, United States
Local Institution - 012-910-A
Huntington Beach, California, United States
Local Institution - 012-910-C
Irvine, California, United States
City Of Hope
Long Beach, California, United States
Start Date
February 23, 2021
Primary Completion Date
December 30, 2023
Completion Date
July 2, 2026
Last Updated
January 22, 2025
NCT06066138
NCT06731413
NCT07222566
NCT07259226
NCT05566223
NCT05676749
Lead Sponsor
Mirati Therapeutics Inc.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions